Discipline of Psychiatry, Sydney Medical School, University of Sydney, Australia.
Aust N Z J Psychiatry. 2013 Apr;47(4):347-54. doi: 10.1177/0004867412474074. Epub 2013 Jan 22.
Increased oxidative stress is thought to contribute to the pathophysiology of major depressive disorder (MDD), which is in part due to diminished levels of glutathione, the primary anti-oxidant of the brain. Oral administration of N-acetyl-cysteine (NAC) replenishes glutathione and has therefore been shown to reduce depressive symptoms. Proton magnetic spectroscopy ((1)H-MRS) that allows quantification of brain metabolites pertinent to both MDD and oxidative biology may provide some novel insights into the neurobiological effects of NAC, and in particular metabolite concentrations within the anterior cingulate cortex (ACC) are likely to be important given the key role of this region in the regulation of affect.
The aim of this study was to determine whether the metabolite profile of the ACC in MDD patients predicts treatment with adjunctive NAC versus placebo.
This study was nested within a multicentre, randomized, double-blind, placebo-controlled study of MDD participants treated with adjunctive NAC. Participants (n = 76) from one site completed the spectroscopy component at the end of treatment (12 weeks). Spectra from a single-voxel in the ACC were acquired and absolute concentrations of glutamate (Glu), glutamate-glutamine (Glx), N-acetyl-aspartate (NAA) and myo-inositol (mI) were obtained. Binary logistic regression analysis was performed to determine whether metabolite profiles could predict NAC versus placebo group membership.
When predicting group outcome (NAC or placebo), Glx, NAA and mI were a significant model, and had 75% accuracy, while controlling for depression severity and sex. However, the Glu, NAA and mI profile was only predictive at a trend level, with 68.3% accuracy. For both models, the log of the odds of a participant being in the NAC group was positively related to NAA, Glx and Glu levels and negatively related to mI levels.
The finding of higher Glx and NAA levels being predictive of the NAC group provides preliminary support for the putative anti-oxidative role of NAC in MDD.
氧化应激的增加被认为是导致重度抑郁症(MDD)病理生理学的原因之一,部分原因是大脑中谷胱甘肽水平降低,而谷胱甘肽是大脑的主要抗氧化剂。口服 N-乙酰半胱氨酸(NAC)可补充谷胱甘肽,因此已被证明可减轻抑郁症状。质子磁共振波谱((1)H-MRS)可定量测量与 MDD 和氧化生物学相关的脑代谢物,这可能为 NAC 的神经生物学效应提供一些新的见解,特别是在前扣带皮层(ACC)中的代谢物浓度可能很重要,因为该区域在调节情绪方面起着关键作用。
本研究旨在确定 MDD 患者 ACC 的代谢物谱是否可预测辅助 NAC 与安慰剂的治疗效果。
这项研究是嵌套在一项多中心、随机、双盲、安慰剂对照的 MDD 患者辅助 NAC 治疗研究中。来自一个地点的 76 名参与者在治疗结束时(12 周)完成了光谱学部分。在 ACC 的单个体素中采集光谱,并获得谷氨酸(Glu)、谷氨酸-谷氨酰胺(Glx)、N-乙酰天冬氨酸(NAA)和肌醇(mI)的绝对浓度。进行二项逻辑回归分析以确定代谢物谱是否可以预测 NAC 与安慰剂组的成员。
在预测组间结果(NAC 或安慰剂)时,Glx、NAA 和 mI 是一个显著的模型,控制抑郁严重程度和性别后,准确率为 75%。然而,Glu、NAA 和 mI 谱仅具有趋势水平的预测能力,准确率为 68.3%。对于这两个模型,参与者处于 NAC 组的对数几率与 NAA、Glx 和 Glu 水平呈正相关,与 mI 水平呈负相关。
发现更高的 Glx 和 NAA 水平可预测 NAC 组,为 NAC 在 MDD 中的潜在抗氧化作用提供了初步支持。